미국의 첨단 창상 관리 OTC 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Advanced Wound Care OTC Market Summary

The U.S. advanced wound care OTC market size was estimated at USD 2.77 billion in 2024 and is projected to reach USD 6.61 billion by 2033, growing at a CAGR of 10.33% from 2025 to 2033. The growth is driven by the increasing prevalence of acute wounds, such as surgical wounds, traumatic injuries, and burns, which require effective and immediate wound management solutions.

Rising rates of road accidents, sports injuries, and surgical procedures globally have led to a surge in demand for advanced OTC wound care products that promote faster healing and reduce the risk of infection. According to the data published by the Total Family Care Center in April 2025, approximately 11 million individuals in the U.S. experience acute wounds annually, with around 300,000 cases requiring hospital care. In addition, the growing awareness among consumers regarding proper wound care practices and the ease of access to advanced dressings through retail pharmacies and online platforms continue to support market expansion.

The high and rising prevalence of diabetes in the U.S. significantly drives the growth of the market. Diabetes is a significant risk factor for the development of chronic wounds, particularly diabetic foot ulcers, which require timely and effective wound management to prevent complications such as infections and amputations. For instance, the Centers for Disease Control and Prevention (CDC) reports that more than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes.

There is an increasing demand for accessible, over-the-counter wound care products that allow individuals to manage minor wounds and prevent them from worsening. Advanced OTC wound care solutions offer diabetic patients a convenient way to treat wounds at home, reducing the need for frequent clinical visits. This growing need for self-care solutions among the diabetic population is a key factor propelling the expansion of the U.S. advanced wound care OTC industry.

U.S. Advanced Wound Care OTC Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. advanced wound care OTC market report based on product, application, and distribution channel.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Foam Dressings
  • Adhesive
  • Non-adhesive Foam Dressings
• Film Dressings
• Hydrocolloids
• Hydrogel Dressings
• Honey Dressings
• Greasy Gauzes
• Non-Woven Post Operative Dressings
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
  • Diabetic Foot Ulcers
  • Pressure Ulcers (Stage 1, Stage 2, Stage 3, Stage 4, and Deep Tissue Injury included)
  • Venous Leg Ulcers
  • Other Chronic Wounds
• Acute Wounds
  • Surgical & Traumatic Wounds (skin tears included)
  • Burns
  • 1st degree burns
  • 2nd degree burns
  • 3rd degree burns
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacies / Drugstores
• E-commerce/Online Pharmacies / Health E-tailers
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Advanced Wound Care OTC Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing adoption of digital distribution platforms
    • 3.2.1.2. Rising burden of wounds
    • 3.2.1.3. Increasing approvals for advanced wound care OTC products
    • 3.2.1.4. Rising aging population in the U.S.
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product recalls
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Shift from institutional settings to home care
    • 3.2.3.2. Increasing number of road accidents and injuries
    • 3.2.3.3. Expansion opportunity in post-surgical wound management
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Advanced Wound Care OTC Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Advanced Wound Care OTC Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Advanced Wound Care OTC Market Movement Analysis
• 4.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Product, 2021 - 2033 (USD Million)
• 4.4. Foam Dressings
  • 4.4.1. Foam Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Adhesive
    • 4.4.2.1. Adhesive Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Non-adhesive Foam Dressings
    • 4.4.3.1. Non-adhesive Foam Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Film Dressings
  • 4.5.1. Film Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Hydrocolloids
  • 4.6.1. Hydrocolloids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Hydrogel Dressings
  • 4.7.1. Hydrogel Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Honey Dressings
  • 4.8.1. Honey Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Greasy Gauzes
  • 4.9.1. Greasy Gauzes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Non-Woven Post Operative Dressings
  • 4.10.1. Non-Woven Post Operative Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Advanced Wound Care OTC Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Advanced Wound Care OTC Market Movement Analysis
• 5.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Chronic Wounds
  • 5.4.1. Chronic Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Diabetic Foot Ulcers (Stage 1, Stage 2, Stage 3, Stage 4 and Deep Tissue Injury included)
    • 5.4.2.1. Diabetic Foot Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Pressure Ulcers
    • 5.4.3.1. Pressure Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Venous Leg Ulcers
    • 5.4.4.1. Venous Leg Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Other Chronic Wounds
    • 5.4.5.1. Other Chronic Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Acute Wounds
  • 5.5.1. Acute Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Surgical & Traumatic Wounds (skin tears included)
    • 5.5.2.1. Surgical & Traumatic Wounds (skin tears included) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Burns
    • 5.5.3.1. Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3.2. 1st Degree Burns
      • 5.5.3.2.1. 1st Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3.3. 2nd Degree Burns
      • 5.5.3.3.1. 2nd Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3.4. 3rd Degree Burns
      • 5.5.3.4.1. 3rd Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Advanced Wound Care OTC Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Advanced Wound Care OTC Market Movement Analysis
• 6.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 6.4. Retail Pharmacies / Drugstores
  • 6.4.1. Retail Pharmacies / Drugstores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. E-commerce/Online Pharmacies / Health E-tailers
  • 6.5.1. E-commerce/Online Pharmacies / Health E-tailers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
• 7.3. Company Share Analysis, 2024
  • 7.3.1. Smith+Nephew
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Product Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Solventum
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Product Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Molnlycke Health Care AB
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Product Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. 3M
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Convatec Inc.
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Lavior
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Vomaris Innovations, Inc.
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. B. Braun SE
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Coloplast Group
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. PAUL HARTMANN AG
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Beiersdorf
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Product Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. Dimora Medical
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Product Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Remedium Healthcare Products
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Product Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Sonoma Pharmaceuticals, Inc.
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Product Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Cardinal Health
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Product Benchmarking
    • 7.3.15.4. Strategic Initiatives
  • 7.3.16. DeRoyal Industries, Inc.
    • 7.3.16.1. Company Overview
    • 7.3.16.2. Financial Performance
    • 7.3.16.3. Product Benchmarking
    • 7.3.16.4. Strategic Initiatives
  • 7.3.17. Medline Industries, LP
    • 7.3.17.1. Company Overview
    • 7.3.17.2. Financial Performance
    • 7.3.17.3. Product Benchmarking
    • 7.3.17.4. Strategic Initiatives
  • 7.3.18. Lavior
    • 7.3.18.1. Company Overview
    • 7.3.18.2. Financial Performance
    • 7.3.18.3. Product Benchmarking
    • 7.3.18.4. Strategic Initiatives